BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July

Day

• 1
• 2
• 3
• 5
• 6
• 7
• 8
• 9
• 10
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27

• Press Releases

  Broad Institute, Boston Children’s Hospital, and The Jackson Laboratory launch the Center for Therapeutic Genetics, a non-profit effort to develop genetic medicines for rare and ultra-rare diseases

  July 21, 2026

   · 

  5 min read
• Press Releases

  Verismo Therapeutics Expands KIR-CAR Solid Tumor Treatment Pipeline with Novel Binder Developed at Penn Targeting Claudin 6 (CLDN6)

  July 21, 2026

   · 

  6 min read
• Press Releases

  Vesalio Announces Late-Breaking Clinical Trial Presentation of the enVast NATURE Study at the ESC Congress 2026

  July 21, 2026

   · 

  2 min read
• Press Releases

  Precigen to Announce Second Quarter 2026 Financial Results and Provide Business Updates on August 4

  July 21, 2026

   · 

  3 min read
• Press Releases

  Pilatus Biosciences Announces Hong Kong Clinical Trial Application Approval for PLT012 and Expansion into Hong Kong

  July 21, 2026

   · 

  3 min read
• Press Releases

  Mastel Surgical Receives FDA 510(k) Clearance for SteriBest Sterilization Tray System

  July 21, 2026

   · 

  2 min read
• Press Releases

  Restore Vision and Forge Biologics Announce AAV Development and cGMP Manufacturing Partnership

  July 21, 2026

   · 

  3 min read
• Press Releases

  AdvanCell to Present Updated Phase 1b Results from the TheraPb Trial at ESMO Congress 2026

  July 21, 2026

   · 

  1 min read
• Press Releases

  Estrigenix Therapeutics Announces Series Seed Financing to Advance ERβ Platform Across Women’s Health and Neurodegenerative Diseases

  July 21, 2026

   · 

  2 min read
• 

  Earnings

  Novartis stays ‘geography-agnostic’ in dealmaking amid flurry of China deals

  Novartis will continue to be on the lookout for bolt-on deals below $2 billion, CEO Vas Narasimhan said Tuesday on the pharma’s second quarter earnings call—though major pickups aren’t completely off the table.

  July 21, 2026

   · 

  2 min read

   · 

  Tristan Manalac